Centene Guides FY26 Adj. EPS Above Estimates As Q4 Results Top Estimates

Centene reported a Q4 net loss attributable of $1.10 billion, or $2.24/share, versus prior-year net income of $283 million ($0.56/share); adjusted loss was $1.19/share compared with prior-year adjusted income of $0.80/share, while quarterly revenue rose to $49.73 billion (Street: $48.35B). The company initiated FY2026 guidance for EPS > $1.98, adjusted EPS > $3.00 and total revenues of approximately $186.5–$190.5 billion, below consensus estimates of $2.99 EPS and $192.47 billion revenue; CNC traded down about 1.05% pre-market following the release.

Analysis

Market structure: Centene’s miss and conservative FY26 revenue guide (186.5–190.5B vs street 192.5B) re-weights winners toward diversified payers (UNH, ELV) and vertically integrated PBM/insurer combos that can better control utilization and Rx costs; small/Medicaid-centric peers (MOH, CST, other state-focused plans) face immediate pricing pressure and potential contract repricing. Higher revenue but adjusted loss signals cost or reserve shocks (utilization, MLR/risk adjustment) that compress margins and shift negotiating leverage back to payors with stronger balance sheets.

Risk assessment: Tail risks include adverse CMS/state capitation rate resets, material risk-adjustment audits, or Medicaid enrollment reversals that could force additional reserves—each could knock equity 20%+ and widen Centene’s credit spreads; immediate (days) = volatility and spread widening, short-term (1–3 months) = guidance re-evals and possible rating action, long-term (6–18 months) = margin recovery depends on cost control and contract renewals. Hidden dependencies: state-level contract renewals and Rx rebate flows; catalyst set = CMS rate filings, investor day, Q1 prints within next 45–90 days.

Trade implications: Tactical short bias on CNC equity/credit with protection; favor pair trades long UNH/ELV vs short CNC to capture relative pricing power. Use directional options to express skew — buy-put spreads on CNC to cap premium outlay and sell short-dated calls on larger payers to fund hedges. Rotate 2–4% portfolio weight from Medicaid-focused small caps into large diversified health insurers and healthcare bonds with IG bias.

Contrarian angle: Consensus discounts Centene’s guide but misses that management still targets adjusted EPS >$3.00 — if cost actions and risk-adjustment tailwinds materialize, stock can rebound 15–30% over 6–12 months. Historical parallels: prior Medicaid/MA shocks produced sharp near-term drawdowns followed by multi-quarter recoveries once reserve clouds cleared. Risk: over-shorting could be squeezed if management unveils aggressive restructuring or asset sales.

Key Decisions for Investors

• Initiate a tactical 3% short position in CNC equity (price ~39.50) with a target = $31.5 (~-20%) and stop-loss = $43.5 (+10%); horizon 1–3 months to capture re-rating if FY guide pressure persists or credit spread widens.
• Establish a 2–3% long position in UNH or ELV financed by the CNC short (pair trade: long UNH 2% / short CNC 3%); hold 3–6 months to capture relative margin resilience if Centene’s guidance revisions continue to lag.
• Buy a 90-day CNC put spread to limit cost: buy Mar-2026 $35 puts and sell Mar-2026 $30 puts sized to equal a 2% portfolio notional exposure; close if CNC trades below $30 or above $46 on sustained daily volume — protects downside while capping premium.
• Reallocate 2–4% of healthcare allocation away from Medicaid-centric small caps into large diversified payers and IG-rated healthcare bonds; monitor CMS/state Medicaid capitation filings and Centene’s investor day within the next 30–60 days—if Centene loses >1 major state contract or guidance is cut >10% from current midpoint, increase short and reduce longs.